Last reviewed · How we verify

NCT05505396: BRAIN-GLULAC

Hyperglycaemia and Hyperlactataemia in Patients With Severe Acute Brain Injury

Completed Last updated 29 July 2025
What this trial tests

trial testing Sampling of blood and cerebrospinal fluid in Acute Brain Injury in 459 participants. Completed in 30 October 2024.

Timeline
24 October 2022
Primary endpoint
30 April 2024
30 October 2024

Quick facts

Lead sponsorRigshospitalet, Denmark
StatusCompleted
Study typeOBSERVATIONAL
Enrollment459
Start date24 October 2022
Primary completion30 April 2024
Estimated completion30 October 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Acute Brain Injury or Hyperglycemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational study of patients with severe acute brain injury, which aims to characterize the development of hyperglycaemia and hyperlactataemia and the influence of these markers on clinical outcome. Additionally, in a subgroup of patients undergoing advanced multimodal neuromonitoring on either clinical or research indication, the relationship between hyperglycaemia and brain glucose levels as well as systemic and microdialysis lactate will be examined.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sampling of blood and cerebrospinal fluid

Trials testing the same drug.

Other recruiting trials for Acute Brain Injury

Currently open trials in the same condition.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05505396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing